GLP-1 medications continue to be one of the defining healthcare and consumer trends of 2026
Oral semaglutide requires daily dosing on an empty stomach with strict timing requirements, whereas injectable semaglutide continues your familiar weekly injection schedule
Egholm C, Khammy MM, Dalsgaard T, et al
Vehicle controls in matched PBS-BSA buffer, GLP-1R antagonist exendin(9-39) confirming GLP-1R specificity, native GLP-1 with DPP-IV inhibitor as the endogenous receptor agonist reference, liraglutide as an intermediate half-life selective GLP-1R agonist comparator, Tirzepatide for dual incretin co-agonism comparison, and matched BSA-only vehicle controls confirming absence of BSA-intrinsic biological effects
The difference likely reflects Wegovy formulation characteristics and its single-dose pen format rather than a fundamental difference in the semaglutide molecule itself